Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that 5q deletion status confers therapeutic sensitivity to Lenalidomide in patients with Myelodysplastic Syndromes.
This statement is based on a regulatory approval from the Health Canada:
REVLIMID (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Approval for this indication is based on red blood cell transfusion independence response rates. Overall survival benefit has not been demonstrated.